Comprehensive Block H Preproffs Study Guide: Pharmacology, Hematology, and Therapeutics
Curricular Organization of Block H Preproffs
Examination Structure and Page Distribution for TMM Super 6 ():
Pharmacology: Page
Neoplasia: Page
Blood Pathology: Page
Immunology: Page
Genetics: Page
Skin and Bone Pathology: Page
Forensic Medicine: Page
Community Medicine: Page
Side Subjects: Page
Autonomic Pharmacology: Cholinergic System
Muscarinic Receptor Actions:
Stimulation of muscarinic receptors located on the sphincter pupillae (circular pupillary muscle) mediates pupillary constriction, designated as meiosis (miosis).
receptor activation does not cause paralysis of the sphincter pupillae, mydriasis, loss of the pupillary light reflex, or inhibition of lacrimation; it actively stimulates lacrimal gland secretion via the phospholipase C–inositol trisphosphate ()–diacylglycerol () pathway.
Muscarinic Toxicity (Pilocarpine Mushroom Ingestion):
Ingestion of mushrooms containing the non-selective muscarinic alkaloid Pilocarpine produces intense parasympathetic toxidromes.
Classical manifestations include:
Bradycardia (via receptors in the sinoatrial node slowing depolarization).
Bronchospasm and intense bronchorrhea (via bronchial receptors stimulating smooth muscle contraction and mucous gland secretion).
Diarrhea and abdominal hypermotility (via intestinal receptors driving hyperperistalsis).
Hyperlacrimation, profuse diaphoresis, and excessive salivation.
Hypertension does not occur following pilocarpine intoxication; instead, muscarinic agonists induce peripheral vasodilation and systemic hypotension via endothelial -mediated nitric oxide () release.
Antimuscarinic Agents and Adverse Effects:
Antimuscarinic Toxicity in Pediatric Populations: In infants and toddlers, the most lethal and dangerous adverse effect of antimuscarinic agents (such as atropine) is hyperthermia ("atropine fever"), stemming from complete inhibition of eccrine sweat gland secretion.
Gastrointestinal Manifestations: Dicyclomine, an antispasmodic anticholinergic indicated for functional bowel disorders and intestinal hypermotility, is recognized clinically for triggering abdominal cramps in atypical or adverse presentations.
Differential Safety of Atropine in the Elderly: While notorious for causing severe complications in elderly populations—exacerbating closed-angle glaucoma, precipitating acute urinary retention in benign prostatic hyperplasia, inducing central antimuscarinic psychosis ("Shezophernia"), and provoking tachyarrhythmias—its bronchodilator action renders its use comparatively less hazardous in patients presenting with bronchial asthma.
Muscarinic Antagonist Selection in Comorbid Cardiac Disease: For a asthmatic patient presenting with comorbid angina pectoris, a competitive muscarinic antagonist that is safe in ischemic heart disease is ipratropium bromide. Being a quaternary ammonium compound, it acts locally within the tracheobronchial tree with negligible systemic absorption, avoiding tachycardia and worsening myocardial oxygen demand.
Distinction Between Ganglionic and Muscarinic Blockade:
Postural hypotension (orthostatic hypotension) serves as the primary differentiating sign distinguishing ganglionic blockers from muscarinic blockers.
Both classes produce peripheral parasympatholytic effects such as xerostomia (dryness of mouth), cycloplegia, blurred vision, constipation, and resting tachycardia.
Ganglionic blockers abolish sympathetic autonomic control over vascular smooth muscle tone, preventing compensatory reflex peripheral vasoconstriction upon upright posture and triggering marked orthostatic pooling and postural hypotension. Muscarinic antagonists do not interrupt sympathetic vascular tone.
Anticholinesterase Agents (Acetylcholinesterase Inhibitors):
Differentiation of Myasthenic vs. Cholinergic Crisis: In a patient with myasthenia gravis presenting to the emergency department with sudden severe limb weakness and diplopia, the rapid-acting, short-duration acetylcholinesterase inhibitor Edrophonium is utilized (Tensilon test). Improvement in muscular weakness confirms a myasthenic crisis (insufficient anticholinesterase therapy), whereas absent improvement or clinical worsening signifies a depolarizing cholinergic crisis (excessive anticholinesterase administration).
Maintenance Therapy in Myasthenia Gravis: Neostigmine is a synthetic quaternary ammonium cholinesterase inhibitor that does not cross the blood-brain barrier (avoiding CNS toxicity), possesses prolonged therapeutic duration, and directly stimulates nicotinic acetylcholine receptors () at the neuromuscular junction.
Comparative Pharmacokinetics of Cholinesterase Inhibitors: Among cholinesterase inhibitors (including edrophonium, physostigmine, neostigmine, and pyridostigmine), Echothiophate possesses the longest duration of action because it forms an extremely stable, irreversible covalent organophosphate-enzyme bond resistant to hydrolytic cleavage.
Neuromuscular Junction Pharmacology:
Succinylcholine is favored in emergency airway management due to its immediate onset () and brief duration () secondary to rapid plasma pseudocholinesterase hydrolysis.
Among non-depolarizing neuromuscular blocking drugs, Rocuronium ("Recuronium") provides the most rapid onset of action, serving as the primary clinical substitute for succinylcholine during rapid sequence tracheal intubation without inducing prolonged neuromuscular blockade or malignant hyperthermia risk.
Autonomic Pharmacology: Adrenergic System
Presynaptic -Adrenoceptor Antagonism:
Yohimbine acts as a selective presynaptic -adrenergic antagonist that is abused as an aphrodisiac and enhancer of sexual performance.
Toxicity Mechanism: Presynaptic adrenoceptors provide negative feedback inhibition against ongoing catecholamine release. Blockade of these receptors by toxic doses of yohimbine triggers massive central and peripheral release of norepinephrine.
Clinical Features: The predominant physiological manifestation of yohimbine overdose is severe hypertension, paired with tachycardia, tremulousness, and anxiety, rather than bradycardia, exocrine hypersecretion, or reduced cardiac contractility.
-Adrenoceptor Agonists:
Phenylephrine: A potent synthetic, directly acting selective -adrenergic receptor agonist devoid of direct -adrenergic activity. It produces intense peripheral arteriolar vasoconstriction, elevating systemic blood pressure with subsequent vagal-mediated reflex bradycardia.
Accidental Decongestant Ingestion: In a child who ingests bottles of over-the-counter nasal decongestant solutions containing topical alpha-adrenergic agonists ("alpha adrenocephalic drug"), selective stimulation of ocular adrenoceptors causes contraction of the radial pupillary dilator muscle, manifesting as dilation of the pupil (mydriasis).
Indirect Sympathomimetic Agents:
Ephedrine is an orally bioavailable, non-catecholamine mixed- and indirect-acting sympathomimetic that stimulates endogenous norepinephrine release and activates adrenoceptors directly.
Clinical Application: Used in pediatric patients (such as a boy) for refractory nocturnal enuresis (bed-wetting), functioning by stimulating receptors at the bladder neck/internal urethral sphincter to increase outflow resistance while lightening deep non-REM sleep stages.
Non-Selective Beta-Adrenoceptor Agonists:
Isoproterenol is a synthetic catecholamine that functions as a potent, non-selective dual - and -adrenergic receptor agonist.
Key properties:
stimulation drives marked positive chronotropy, inotropy, and dromotropy.
stimulation drives profound peripheral vasodilation and powerful bronchodilation (relieving rather than inducing bronchospasm).
It is not contraindicated in atrioventricular block; rather, it is indicated for the acute emergent treatment of refractory complete heart block and severe bradyarrhythmias.
Dopaminergic Agonists and Hemodynamics:
Dopamine is an endogenous catecholamine exhibiting dose-dependent multi-receptor pharmacology:
Low doses (): Activates vascular receptors in renal, mesenteric, and coronary vascular beds, producing vasodilation, increasing renal blood flow, enhancing glomerular filtration rate, and boosting urinary volume/natriuresis.
Intermediate doses (): Stimulates cardiac receptors, exerting positive inotropic and chronotropic effects.
High doses (): Stimulates peripheral receptors, inducing widespread arterial vasoconstriction.
Physiological Inaccuracy: Dopamine does not typically decrease urinary flow or renal output through extreme vasoconstriction at physiological or moderate therapeutic doses; it is clinically utilized to preserve and increase renal blood flow.
Alpha-1 Receptor Blockers in Benign Prostatic Hypertrophy (BPH):
Terazosin is a selective, long-acting quinazoline-derived -adrenergic antagonist.
It produces rapid clinical relief of urinary outflow obstruction by relaxing smooth muscle in the prostatic stroma, prostatic capsule, and bladder neck.
Compared to -reductase inhibitors like Finasteride—which require to reduce prostate epithelial volume— blockers provide rapid and superior symptomatic relief within days to weeks.
Beta-Adrenergic Blockers with Intrinsic Sympathomimetic Activity (ISA):
Pindolol is a non-selective -adrenergic antagonist that possesses Intrinsic Sympathomimetic Activity (ISA / partial agonist properties) alongside membrane-stabilizing activity (quinidine-like local anesthetic action).
Hemodynamic Effect: While competing with endogenous catecholamines to exert antihypertensive effects, its low-grade intrinsic basal receptor stimulation prevents resting bradycardia, making it suitable for hypertensive patients who exhibit resting sinus bradycardia.
Rheumatoid Arthritis and Anti-Inflammatory Therapeutics
Clinical Presentation of Rheumatoid Arthritis:
Rheumatoid arthritis (RA) characteristically presents as an inflammatory polyarthritis featuring morning stiffness that lasts greater than and characteristically improves with physical activity and joint use.
In contrast, degenerative non-inflammatory joint disorders like osteoarthritis worsen with prolonged weight-bearing activity and improve with rest.
Conventional Synthetic Disease-Modifying Anti-Rheumatic Drugs (csDMARDs):
csDMARDs slow or arrest underlying radiographic joint destruction and alter the natural course of rheumatoid arthritis.
Standard csDMARD agents include Methotrexate (first-line anchor csDMARD), Sulfasalazine, Leflunomide, and Hydroxychloroquine.
Naproxen sodium is an anti-inflammatory NSAID; it provides rapid analgesic and anti-inflammatory symptomatic relief but does not prevent radiographic joint erosion, bone deformities, or disease progression, and is thus excluded from classification as a DMARD.
Toxicity Profile of Hydroxychloroquine:
Hydroxychloroquine is an antimalarial agent used as an adjunct csDMARD alongside NSAIDs like ibuprofen in mild RA.
Adverse effects include central nervous system disturbances (dizziness, headaches) and ocular complications:
Reversible corneal microdeposits/corneal opacity causing halos and blurriness of vision.
Irreversible chloroquine/hydroxychloroquine retinopathy (maculopathy featuring a "bull's-eye" appearance) resulting from retinal pigment epithelial accumulation.
Biologic Disease-Modifying Anti-Rheumatic Drugs (Biologics / bDMARDs):
Biological Response Modifiers represent genetically engineered protein molecules designed to target specific extracellular cytokines, cell-surface costimulatory molecules, or immune cell populations:
Anti-TNF- Monoclonal Antibodies: Adalimumab is a recombinant human IgG1 monoclonal antibody that binds directly to soluble and transmembrane tumor necrosis factor-alpha (), neutralizing its biological interaction with and cell-surface TNF receptors.
Alternative Biologics: Etanercept (recombinant human fusion protein) and Rituximab (chimeric anti-CD20 monoclonal antibody inducing B-cell depletion).
Distinction from Small-Molecule Synthetics: Small-molecule non-biologic antimetabolites like Methotrexate are not biological response modifiers; they are synthesized chemical agents inhibiting dihydrofolate reductase and AICAR transformylase, rather than genetically engineered antibody proteins.
Hematology: Anemia Subtypes and Pathophysiology
Anemia of Chronic Disease (ACD) in Long-Standing Inflammation:
In a female with rheumatoid arthritis on chronic NSAID therapy presenting with low serum iron and low Total Iron Binding Capacity (TIBC / low iron-binding capacity):
Laboratory Parameters: Hepcidin expression is driven by inflammatory cytokines (), which degrades ferroportin-1, traps iron within the reticuloendothelial storage pool (ferritin), and prevents transferrin release.
Diagnostic Hallmarks: Low serum iron, reduced TIBC/transferrin concentration, normal or elevated serum ferritin, and reduced transferrin saturation.
Classification: Presents morphologically as a normocytic or microcytic hypochromic anemia (microcytic anemia).
Differential Distinction: Classical iron deficiency anemia (IDA) presents with low serum iron paired with a characteristically elevated TIBC (reflecting upregulated transferrin synthesis).
Megaloblastic Anemia Post-Gastrectomy:
Clinical Scenario: A female with a history of gastrectomy performed prior for pyloric stenosis presents with macrocytosis (elevated Mean Corpuscular Volume / high MCV) and elevated methylmalonic acid ().
Pathophysiology: Surgical resection of the gastric fundus and body eliminates gastric parietal cells, causing total cessation of Intrinsic Factor () synthesis. Vitamin (cyanocobalamin) requires binding to intrinsic factor to facilitate receptor-mediated endocytosis via cubam receptors in the terminal ileum. Because hepatic cobalamin stores () become depleted over several years (), severe megaloblastic anemia develops.
Biochemical Marker: Methylmalonyl-CoA mutase requires cobalamin as an essential cofactor to convert methylmalonyl-CoA to succinyl-CoA. In cobalamin deficiency, elevated methylmalonic acid occurs, distinguishing it from folate deficiency (where remains normal).
Definitive Management: Because physiological intestinal absorption is abolished in the absence of intrinsic factor, oral cyanocobalamin is inadequate; management requires lifelong parenteral cyanocobalamin (intramuscular injections).
Oncology and Immunosuppressive Drug Toxicities
Anticancer Drug Toxicities:
Cisplatin ("Cisplastin"): An inorganic platinum coordination alkylating-like agent notable for inducing severe, dose-limiting acute and chronic nephrotoxicity (tubular necrosis) and ototoxicity, while exhibiting minimal to absent bone marrow suppression relative to conventional cytotoxic agents.
Cyclophosphamide: Generates acrolein leading to dose-dependent hemorrhagic cystitis alongside classical myelosuppression.
Bleomycin: Generates free radicals causing pulmonary interstitial pneumonitis and dose-limiting pulmonary fibrosis, with minimal bone marrow suppression.
Methotrexate: Induces classic myelosuppression, mucositis, and acute hepatic enzyme elevations.
Toxic Profiles of Immunosuppressive Therapies:
Anti-CD3 Monoclonal Antibodies (Muromonab-CD3): Triggers massive systemic cytokine release syndrome within hours of administration, manifesting with fever, chills, rigors, and flu-like symptoms.
Corticosteroids: Trigger secondary hyperglycemia, cushingoid changes, osteoporosis, and increased opportunistic infection susceptibility.
Mycophenolate Mofetil (): Primarily produces dose-limiting gastrointestinal disturbances (severe diarrhea, abdominal pain, nausea) and secondary electrolyte/electric imbalances via mucosal inosine monophosphate dehydrogenase () inhibition.
Cyclosporine Classical Toxicity Profile: The hallmark dose-limiting toxicity of cyclosporine (a calcineurin inhibitor) is nephrotoxicity and secondary systemic hypertension, alongside gingival hyperplasia and hirsutism. It does not cause classical dose-limiting bone marrow depression.
Critical Drug Interaction: 6-Mercaptopurine and Allopurinol:
Clinical Context: In solid organ transplant recipients maintained on immunosuppressive antimetabolites who develop secondary hyperuricemia or clinical gout:
Mechanism of Interaction: -Mercaptopurine ()—the active cytotoxic metabolite of azathioprine—is catabolized into an inactive form (6-thiouric acid) by the hepatic and intestinal enzyme xanthine oxidase.
Toxicity Risk: Allopurinol is an irreversible inhibitor of xanthine oxidase. Concomitant administration abolishes the primary degradation pathway of , triggering severe accumulation of active nucleotides (), causing lethal bone marrow aplasia and profound pancytopenia.
Management: The therapeutic dosage of -mercaptopurine must be drastically reduced by (administering only of the standard dose) when co-administered with allopurinol.
Cardiovascular Emergency Management
Acute Coronary Syndrome (ACS) Presentation:
Case Presentation: A male with documented stable angina presents with an acute, sudden transition to severe persistent chest pain, profuse diaphoresis, dyspnea, and palpitations.
Hemodynamic Signs: Significant hypertension () and marked sinus tachycardia ().
Clinical Assessment: This presentation reflects an acute coronary event (unstable angina or non-ST-elevation myocardial infarction) marked by acute adrenergic surge, severe coronary ischemia, and increased myocardial wall stress.
Immediate Pre-Hospital/Pre-MTI Stabilization:
Prior to urgent transfer to a specialized medical tertiary institute (MTI), immediate management mandates the oral co-administration of chewed aspirin and nitrates.
Mechanism: Chewed, non-enteric coated oral aspirin achieves rapid thromboxane () synthesis inhibition, blocking platelet aggregation at the site of unstable plaque rupture.
Sublingual or oral nitrates generate nitric oxide, inducing peripheral venodilation to decrease ventricular preload, diminish end-diastolic wall tension, reduce myocardial oxygen demand, and relieve coronary arterial vasospasm.